Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration

Open access

Abstract

Purpose: To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. Patients and methods: Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. Results: A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). Conclusion: According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12886-022-02761-9

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Anti-aflibercept values in the samples and the limit of detection (dotted line)
Fig. 1 Anti-aflibercept values in the samples and the limit of detection (dotted line)CC BY · PubMed Central
Fig. 2 Correlation of the number of intravitreal injections with the aqueous level non-specific and specific anti-aflibercept immunglobulins
Fig. 2 Correlation of the number of intravitreal injections with the aqueous level non-specific and specific anti-aflibercept immunglobulinsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 20

  1. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains eye study. J Am Geriatr Soc. 1998;46(1):58–64. https://doi.org/10.1111/j.1532-5415.1998.tb01014.x. · DOI · Paper page
  2. West SK, Munoz B, Rubin GS, Schein OD, Bandeen-Roche K, Zeger S, et al. Function and visual impairment in a population-based study of older adults. The SEE project. Salisbury eye evaluation. Invest Ophthalmol Vis Sci. 1997;38(1):72–82.
  3. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  4. Eghøj MS, Sørensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;96(1):21–3. https://doi.org/10.1136/bjo.2011.203893. · DOI · Paper page
  5. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  6. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  7. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. https://doi.org/10.1056/NEJMoa054481. · DOI · Paper page
  9. Chen M, Xu H. Parainflammation, chronic inflammation, and age-related macular degeneration. J Leukoc Biol. 2015;98(5):713–25. https://doi.org/10.1189/jlb.3RI0615-239R. · DOI · Paper page
  10. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21(Suppl 6):S3–9. https://doi.org/10.5301/EJO.2010.6049. · DOI · Paper page
  11. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
  12. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond). 1995;9(Pt 2):236–40. https://doi.org/10.1038/eye.1995.46. · DOI
  13. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
  14. Streilein JW. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res. 1999;18(3):357–70. https://doi.org/10.1016/s1350-9462(98)00022-6. · DOI
  15. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;29(6):723–31. https://doi.org/10.1097/IAE.0b013e3181a2c1c3. · DOI · Paper page
  16. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  17. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  18. Hara C, Wakabayashi T, Fukushima Y, Sayanagi K, Kawasaki R, Sato S, et al. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. Graefes Arch Clin Exp Ophthalmol. 2019;257:2559–69. https://doi.org/10.1007/s00417-019-04456-2. · DOI
  19. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;2(10):1857–67. https://doi.org/10.2147/DDDT.S97653. · DOI · Paper page
  20. Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22(2):116–26. https://doi.org/10.1038/gt.2014.115. · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S.
Affiliations
  • Semmelweis University (HU)
  • Eötvös Loránd University (HU)
  • Cornell University (US)
Corresponding author
Kovács, Illés
Venue
BMC Ophthalmology
Published
2023-01-10
Volume
23
Issue
1
Pages
14-14
ISSN
1471-2415 (ISSN-L)
OpenAlex
W4313892309
Cited by
9
References
55
Citations by year
2026: 1 · 2025: 5 · 2024: 3
FWCI
2.19
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Ophthalmology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Semmelweis University
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
aflibercept, age-related macular degeneration, neutralizing antibodies, aqueous humor, intravitreal injection, anti-VEGF therapy, tachyphylaxis, blood-retinal barrier, choroidal neovascularization, IgG
MeSH terms
Ranibizumab, Aged, Aged, 80 and over, Cataract, Humans, Immunoglobulin G, Middle Aged, Recombinant Fusion Proteins, Visual Acuity, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Antibodies, Neutralizing, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. https://app.cochat.ai/papers/10.1186/s12886-022-02761-9
The paper
Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S. (2023). Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration. BMC Ophthalmology. https://doi.org/10.1186/s12886-022-02761-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.